Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers

This is a prospective, open label navigational investigation to evaluate the feasibility of
using molecular profile-based evidence to determine individualized cancer therapy for
patients with incurable malignancies. This is a non-randomized, histology-agnostic trial.
While it is known that individual histologies are composed of a heterogeneous mix of genomic
alterations, it is not clear that one case mix is better or worse than another. Thus, a
strategy of molecular matching that may apply across cancers is being tested. All eligible
and consented patients will have their tumor tissues genomic profiled by Foundation
Medicine's FoundationOne genomic analysis. Patients will be stratified into Group 1
(treatment naïve, unresectable/medically unfit for surgery), Group 2 (treatment naïve,
metastatic), and Group 3 (prior treated), respectively. Following analysis for genomic
alterations, matched therapy, if available, will be recommended by the Study Committee or
Molecular Tumor Board. If the patients received the matched therapy, they are designated as
in Arm A. Otherwise, if the patients received the unmatched therapy (i.e., treating
physician's choice of traditional systemic chemotherapy), they are designated as in Arm B.
The study feasibility will be measured by the ability to enroll patients, the acceptable
turnaround time and the actionable information obtained from the genomic profiling, and the
viability of identifying and delivering the matched therapy. The treatment efficacy will be
determined among the patients groups and treatment arms. The safety profile of the treatment
will also be assessed.

Inclusion Criteria Patients must meet all of the inclusion criteria to participate in this
study.

1. Patients with incurable malignancies with more than 50% 2-year cancer-associated
mortality (as estimated by two physician and where appropriate according to 2014
National Cancer database)

Diseases include, but are not limited to:

Ampullary carcinoma Intrahepatic cholangiocarcinoma (IHCC) Appendiceal cancer Melanoma
Colorectal cancer (CRC) Non-KIT GIST (gastrointestinal stromal tumor) Extrahepatic
cholangiocarcinoma (EHCC) Non-small cell lung cancer (NSCLC) Esophageal adenocarcinoma
Ovarian cancer Gallbladder cancer (GBCA) Pancreatic ductal adenocarcinoma (PDAC)
Gastric adenocarcinoma Sarcoma (high-grade) Head and neck cancer Small bowel
adenocarcinoma (including duodenal) Hepatocellular carcinoma (HCC) Triple-negative
breast cancer (TNBC) Urothelial cancer

2. Patients with cancer of unknown primary or a rare tumor (for example, fewer than 15
cases per 100,000 per year) with no approved therapies. (Patients in this inclusion
criteria must meet all other exclusion and inclusion criteria except inclusion
criteria #1)

3. Patients with incurable malignancies, irrespective of 2-year mortality, who, in the
opinion of the investigator have no treatment option expected to yield significant
clinical benefit."

4. Patients must have at least one of the following for a diagnosis/disease status:

1. Unresectable disease

2. Metastatic disease

3. Medically unfit for surgical resection but with an expected survival of > 3
months, ECOG < 2 and NYHA status ≤ II (refer to status definitions in tables
below)

4. Disease where no conventional therapy leads to a survival benefit > 6 months in
the respective cohort and line of therapy for which the patient is otherwise
eligible

5. Actionable alterations determined by FoundationOneTM

5. Treatment naïve for his or her newly diagnosed malignancy for enrollment to Groups 1
or 2.

6. Status post 1 or more unmatched systemic therapy regimens for enrollment to Group 3.

7. Ability to understand and the willingness to sign a written informed consent.

8. Patients must have measurable disease for malignancies: defined as at least one lesion
that can be accurately measured in at least one dimension (longest diameter to be
recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with
conventional techniques or as ≥10 mm with spiral CT scan, PET-CT, MRI, or calipers by
clinical exam.

9. Age ≥ 18 years.

10. ECOG Performance Status 0-1.

Grade Description 0 Fully active, able to carry on all pre-disease performance without
restriction 1 Restricted in physically strenuous activity but ambulatory and able to
carry out work of a light or sedentary nature, e.g., light housework or office work 2
Ambulatory and capable of all self-care but unable to carry out any work activities.
Up and about >50% of waking hours 3 Capable of only limited self-care, confined to a
bed or chair >50% of waking hours 4 Completely disabled. Cannot carry on any
self-care. Totally confined to bed or chair 5 Dead

11. New York Heart Association (NYHA) Functional Classification I-II.

NYHA Class Symptoms I Cardiac disease, but no symptoms and no limitation in ordinary
physical activity, e.g. shortness of breath when walking, climbing stairs etc.

II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during
ordinary activity.

III Marked limitation in activity due to symptoms, even during less-than-ordinary
activity, e.g. walking short distances (20-100 m).

Comfortable only at rest. IV Severe limitations. Experiences symptoms even while at
rest. Mostly bedbound patients.

12. Adequate organ and marrow function as defined below:

- Absolute neutrophil count ≥ 1.5 x 109/L

- Platelet count ≥ 100 x 109/L

- Total bilirubin ≤ 2.0 x institution's ULN

- Patients without underlying liver disease

o ALT and AST ≤ 2.5 X institutional upper limit of normal

- Serum creatinine ≤ 2.0 x institution's ULN or 24-hour creatinine clearance ≥ 50
ml/min

13. At the time of treatment, patients should be off other anti-tumor agents for at least
5 half-lives of the agent or 3 weeks from the last day of treatment, whichever is
shorter to enroll in Group 3. Patients must not have been treated with anti-tumor
agents to enroll in Group 1 or Group 2. Patients must be off prior antibody therapy
for at least 3 half-lives before starting treatment. Patients may enroll on study even
while receiving treatment.

14. Able to swallow and retain oral medication if needed.

15. Patients must have evaluable tissue/blood for testing as specified by the concurrent
FoundationOneTM criteria. This will be obtained during the standard of care tumor
diagnosis and tumor staging evaluation.

16. Female patients of childbearing potential must have a negative serum pregnancy test
and agree to use at least one form of pregnancy prevention during the study and for at
least one month after treatment discontinuation. For the purposes of this study,
child- bearing potential is defined as: all female patients that were not in post-
menopause for at least one year or are surgically sterile (site-specific criteria
applying to Avera only)

17. Male patients must use a form of barrier pregnancy prevention approved by the
investigator / treating physician during the study and for at least one month after
treatment discontinuation (site-specific criteria applying to Avera only).

Exclusion Criteria Subjects meeting any of the exclusion criteria at baseline will be
excluded from study participation.

1. Two oncologists disagree on prognosis or resectability.

2. Severe or uncontrolled medical disorder that would, in the investigator's opinion,
confound study analyses of treatment response (i.e., uncontrolled diabetes, chronic
renal disease, chronic pulmonary disease or active, uncontrolled infection,
psychiatric illness/social situations that would limit compliance with study
requirements).

3. Are pregnant or breast-feeding patients or any patient with childbearing potential not
using adequate pregnancy prevention (site-specific criteria applying to Avera only).